Pulmonary Artery Sensor System Articles & Analysis
18 news found
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on Wednesday, November 30, 2022, at 11:30 AM PT / 2:30 PM ET. A live and archived webcast of the presentation will be available ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. Pulmonx management is scheduled to participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 16, 2022, at 8:00AM ET. Interested ...
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose. ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 27, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 10, 2022, at 1:00 PM PT / 4:00 PM ET. ...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, MD, President and CEO, will present at the H.C. Wainwright BIOCONNECT Virtual Conference, taking place from January 10 – 13, 2022. H.C. Wainwright BIOCONNECT Conference Date: January 10 – 13, 2022 Presentation Time: Available on-demand January 10, 2022 at 7:00 am ET Webcast: ...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor.(1) Under ...
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced positive data from the SIRONA 2 clinical trial evaluating safety and efficacy of its Cordella™ Pulmonary Artery Pressure Sensor System (Cordella Sensor) in New York ...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Biopas Laboratories today announced that they have entered into distribution and supply agreements to commercialize INBRIJA in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Bank of America Securities 2022 Healthcare Conference in Las Vegas. Management is scheduled to present on Tuesday, May 10, 2022, at 12:40 PM PT / 3:40 PM ET. A live and archived webcast of the presentation ...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that John Varian has joined its board of directors, effective January 1, 2022. “We are delighted that John has joined Acorda’s board of directors,” said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer. “We expect his insights and counsel to contribute significantly as we continue to make ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions, announced today that the Food and Drug Administration (FDA) has granted it's lead compound, ENA-001, rare pediatric disease designation for the treatment of Apnea of Prematurity. Enalare is planning to develop this unique agnostic ...
The trial is a pre-market investigational device exempt (IDE) study evaluating the safety and efficacy of the Cordella™ Pulmonary Artery (PA) Pressure Sensor System (Cordella Sensor) for the treatment of HF. ...
-based Endotronix, Inc. and Tyndall will explore the application of novel electronics technologies to wireless, implantable sensors for chronic disease management, such as the Cordella Pulmonary Artery Pressure Sensor System (Cordella Sensor). “Together our Cordella Sensor ...
The funds will be used to support the landmark PROACTIVE-HF IDE clinical trial of the Cordella Pulmonary Artery Sensor System (Cordella Sensor) and commercialization of the Cordella Heart Failure System (Cordella System). ...
The 60-patient study will evaluate safety and efficacy of the Cordella™ Pulmonary Artery Pressure Sensor System (Cordella Sensor) in support of its CE Mark submission. ...
Thirty-seven proclamations for multiple chemical sensitivity (MCS), toxic injury (TI), or chemical sensitivity (CS) have been signed by governors of 34 states! This year’s proclamations represent the largest signing of any past year, indicating increased awareness of these debilitating environmental illnesses. Multiple chemical sensitivity is an environmental illness which causes negative ...